We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

74 hedge funds and large institutions have $53.2M invested in Invesco Biotechnology & Genome ETF in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

7% more funds holding

Funds holding: 69 → 74 (+5)

2% more capital invested

Capital invested by funds: $52.3M → $53.2M (+$896K)

0.07% less ownership

Funds ownership: 22.16% → 22.09% (-0.07%)

41% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 22

Holders
74
Holders Change
+5
Holders Change %
+7.25%
% of All Funds
1.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
13
Reduced
22
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PSF
Pacific Sun Financial
California
+$662K
2
Jane Street
Jane Street
New York
+$390K
3
HighTower Advisors
HighTower Advisors
Illinois
+$311K
4
Morgan Stanley
Morgan Stanley
New York
+$309K
5
BRWA
B. Riley Wealth Advisors
Florida
+$212K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$1.52M
2
Wells Fargo
Wells Fargo
California
-$345K
3
TAM
Trillium Asset Management
Massachusetts
-$320K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$237K
5
Bank of America
Bank of America
North Carolina
-$233K
Name Holding Trade Value Shares
Change 		Change in
Stake
JCM
51
Jacobi Capital Management
Pennsylvania
$57K – – –
SWP
52
Stratos Wealth Partners
Ohio
$46K -$3.83K -75 -7%
SEI Investments
53
SEI Investments
Pennsylvania
$46K – – –
LF
54
Lee Financial
Texas
$38K – – –
Manulife (Manufacturers Life Insurance)
55
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$30K – – –
APA
56
American Portfolios Advisors
New York
$25.8K – – –
FANJ
57
Financial Architects (New Jersey)
New Jersey
$25K – – –
Carson Wealth (CWM LLC)
58
Carson Wealth (CWM LLC)
Nebraska
$21K – – –
William Blair & Company
59
William Blair & Company
Illinois
$20K +$20.4K +400 New
IWM
60
IHT Wealth Management
Illinois
$16K – – –
RFA
61
Reilly Financial Advisors
California
$15K – – –
CAPTRUST Financial Advisors
62
CAPTRUST Financial Advisors
North Carolina
$12K – – –
GFP
63
Gryphon Financial Partners
Ohio
$11K +$3.01K +59 +37%
AIM
64
Advantage Investment Management
Iowa
$10K – – –
ME
65
McIlrath & Eck
Washington
$10K – – –
PCM
66
Peak Capital Management
Colorado
$10K +$10K +196 New
S
67
SignatureFD
Georgia
$10K +$10.9K +213 New
EWM
68
Elmwood Wealth Management
California
$9.84K +$10.2K +200 New
ASN
69
Advisory Services Network
Georgia
$9K – – –
WAM
70
Wealthspire Advisors (Maryland)
Maryland
$5K – – –
AIP
71
Ameritas Investment Partners
Nebraska
$2K – – –
RFC
72
Regions Financial Corp
Alabama
$1K – – –
RWA
73
Ropes Wealth Advisors
Massachusetts
$1K +$969 +19 New
TAM
74
Trillium Asset Management
Massachusetts
– -$320K -6,795 Closed
CA
75
Calton & Associates
Florida
– -$28K -544 Closed
1 2
3
4

PBE Hedge Fund Activity: Q1 2018 in Review

74 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2018, worth a combined $53.2M — up 1.7% from $52.3M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PBE positions and 4 closed out — a net gain of 5 holders — while 13 added to existing stakes and 22 trimmed.

The largest buyer was Pacific Sun Financial, opening a new position worth an estimated $662K. The largest seller was Virtu Financial, cutting an estimated $1.52M.

  • 74 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2018, up from 69 in Q4 2017.
  • Funds reported $53.2M of Invesco Biotechnology & Genome ETF stock for Q1 2018, up 1.7% quarter-over-quarter.
  • 9 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2018 and 4 closed out, a net change of +5 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q1 2018 was Pacific Sun Financial, an estimated $662K added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q1 2018 was Virtu Financial, an estimated $1.52M sold.

Based on aggregated 13F filings for Q1 2018.